About RDI
Translating scientific discovery into practical development through international collaboration
3
Countries
13+
Research Partners
6
Active Programs
EU
Innovation Radar
EU Innovation Radar — Key Innovator (2025)
RDI was identified as a Key Innovator by the European Commission’s Innovation Radar for the development of a cardio-protective drug through the Horizon Europe-funded PULSE project. The innovation was assessed as Business Ready with High Market Creation Potential.
Our Mission
RDI develops biotechnology and medical research programs focused on biological resilience and protection in both clinical and extreme environments.
Our mission is to translate scientific discovery into practical development activities through international collaboration — spanning oncology, radiation-related research, and space-relevant health challenges.
How We Operate
RDI is led by a core team spanning translational research, pharmacology, radiation biology, and program development.
We work with a network of academic and institutional collaborators across the U.S. and Europe to advance research and development activities.
Key Collaborators & Partners
Selected academic and institutional partners across the U.S. and Europe
NIAID
USA
Radiation countermeasure research
SRI International
USA
Biosciences research support
Univ. of Illinois Chicago
USA
Clinical & translational research
Medical Univ. of Graz
Austria
Cardiotoxicity & radioprotective drug testing
Univ. of Maryland
USA
Biochemical & pharmacological studies
Maastricht University
Netherlands
Biomedical engineering
SCK CEN
Belgium
Radiation biology & space research
Space Applications Services
Belgium
Space medicine & human health
Lovelace Biomedical
USA
Preclinical & radiation research
ESA
Europe
Space medicine & human spaceflight
Otto-von-Guericke Univ. Magdeburg
Germany
Cardiac models in simulated space
Metatissue
Portugal
Protein materials & cryopreservation
InSociety
Italy
Communication & exploitation